Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

A drug commonly used to treat type 2 diabetes may reduce excess fluid in the brains of patients with hydrocephalus, which ...

A study published in JAMA Surgery involving nearly 500,000 surgeries among U.S. veterans found that patients taking SGLT2 ...

Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

Whether you’re newly diagnosed with type 2 diabetes or have been managing it for many years, asking your doctor the right ...

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

Dr. Dustin T. Smith and Dr. Joanna M. Bonsall reviewed nine key updates in hospital medicine at SHM Converge 2025.

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted BioCity's endothelin receptor type A (ET A) antagonist, SC0062, a second breakthrough ...

Subscribe to UCSF NewsA UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of ...